These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 845257)

  • 21. Systemic lupus erythematosus, partial lipodystrophy and hypocomplementemia.
    Jasin HE
    J Rheumatol; 1979; 6(1):43-50. PubMed ID: 439110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative pathway complement activation in rheumatoid arthritis.
    El-Ghobarey A; Whaley K
    J Rheumatol; 1980; 7(4):453-60. PubMed ID: 6158571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Staphylococcus aureus bacteremia.
    Cunnion KM; Benjamin DK; Hester CG; Frank MM
    J Lab Clin Med; 2004 Jun; 143(6):358-65. PubMed ID: 15192652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arthritis associated with chronic active hepatitis: complement activation and characterization of circulating immune complexes.
    Wands JR; Alpert E; Isselbacher KJ
    Gastroenterology; 1975 Dec; 69(6):1286-91. PubMed ID: 1193327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complement component C5: engineering of a mutant that is specifically cleaved by the C4-specific C1s protease.
    Ogata RT; Low PJ
    J Immunol; 1995 Sep; 155(5):2642-51. PubMed ID: 7650393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.
    Adu D; Williams DG
    Clin Exp Immunol; 1984 Mar; 55(3):495-501. PubMed ID: 6705265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.
    Alper CA; Abramson N; Johnston RB; Jandl JH; Rosen FS
    J Clin Invest; 1970 Nov; 49(11):1975-85. PubMed ID: 4097977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Active sites in complement components C5 and C3 identified by proximity to indels in the C3/4/5 protein family.
    Low PJ; Ai R; Ogata RT
    J Immunol; 1999 Jun; 162(11):6580-8. PubMed ID: 10352274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
    Arnaout MA; Davis AE; Rosen RS; Alper CA
    J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between the component and regulatory proteins of the classical pathway C3 convertase.
    Welch TR; Forristal J; Beischel L
    J Lab Clin Med; 1986 Jun; 107(6):529-33. PubMed ID: 3635565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of C3 nephritic factor on the complement system--with special reference to stabilizing effect on C3 convertase (C3bBb) activity (author's transl)].
    Nakanishi I
    Nihon Jinzo Gakkai Shi; 1981 Jun; 23(6):719-32. PubMed ID: 6914399
    [No Abstract]   [Full Text] [Related]  

  • 32. Mesangiocapillary glomerulonephritis associated with meningococcal meningitis, C3 nephritic factor and persistently low complement C3 and C5.
    Hulton SA; Risdon RA; Dillon MJ
    Pediatr Nephrol; 1992 May; 6(3):239-43. PubMed ID: 1616831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.
    Charlesworth JA; Williams DG; Sherington E; Lachmann PJ; Peters DK
    J Clin Invest; 1974 Jun; 53(6):1578-87. PubMed ID: 4830223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial: Glomerulonephritis, complement and C3NeF.
    Fearon DT
    N Engl J Med; 1976 Feb; 294(9):495-7. PubMed ID: 1246336
    [No Abstract]   [Full Text] [Related]  

  • 35. Hereditary deficiency of the fifth component of complement in man. I. Clinical, immunochemical, and family studies.
    Rosenfeld SI; Kelly ME; Leddy JP
    J Clin Invest; 1976 Jun; 57(6):1626-34. PubMed ID: 932197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism of human beta 1H: studies in man and experimental animals.
    Charlesworth JA; Scott DM; Pussell BA; Peters DK
    Clin Exp Immunol; 1979 Dec; 38(3):397-404. PubMed ID: 535181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The metabolism of C3 in adult coeliac disease.
    Brinch L; Teisberg P; Fausa O; Akesson I
    Scand J Gastroenterol; 1980; 15(1):33-8. PubMed ID: 7367819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complement and clinical intervention.
    Watkins J
    Ann Fr Anesth Reanim; 1985; 4(2):129-32. PubMed ID: 3890626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Action of complement in normal pregnancy and gestosis].
    Manno C; Loverro G; Selvaggi L; Pepe M; Schena FP
    Boll Ist Sieroter Milan; 1979 Sep; 58(4):325-34. PubMed ID: 261756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complement activity in normal rabbit bronchoalveolar fluid. Description of an inhibitor of C3 activation.
    Giclas PC; King TE; Baker SL; Russo J; Henson PM
    Am Rev Respir Dis; 1987 Feb; 135(2):403-11. PubMed ID: 3643768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.